- Prasco will market the adult rheumatoid arthritis treatment of sanofi-aventis’ Arava®
- Prasco’s Leflunomide Tablets is the Authorized Generic and is AB-Rated to the brand Arava®

CINCINNATI; September 14, 2005 — Prasco Laboratories, a privately held pharmaceutical company located in Cincinnati, Ohio, announced today it has begun shipping its Leflunomide Tablets. Leflunomide is a Prasco Authorized Generic of sanofi-aventis’ Arava® indicated for the treatment of adult rheumatoid arthritis.

“We have begun shipping the leflunomide product today, as planned,” said Prasco Chief Executive Officer E. Thomas Arington. “We are very pleased to provide pharmacists and consumers with the Authorized Generic of Arava,” Arington concluded.

About Prasco
Prasco’s mission is to provide both quality products and significant cost-savings to the consumer with Prasco Independent Authorized Generics. Prasco’s goal is to provide patients with brand sameness through Prasco Authorized Generics, which are brand products sold under the Prasco private label. Prasco’s executive team has extensive experience working within both the brand and generic industries. A centerpiece of the company’s corporate capabilities is its sales/marketing and business development teams. Prasco’s product line is currently sold through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers.

The company operates from a 54,000 sq. ft. administrative office and warehouse facility and has complete control over product distribution management systems—including DEA-approved facilities for Schedule II-V controlled drug products.

###

CONTACT:
Kimberly Carroll, Vice President Communications & Marketing Services
Prasco Laboratories
513-618-3333
website: www.prasco.com
www.authorizedgenerics.com